Answers are grounded in this paper and cite their sources.
OBJECTIVE: To evaluate changes in basal serum cortisol levels in patients with atrophic-erosive oral lichen planus (OLP) and oral lichenoid lesion (OLL) treated with 0.5% triamcinolone acetonide mouthrinses and to assess the occurrence of clinical manifestations associated with adrenal dysfunction. METHODS: A prospective observational study was conducted in 68 patients with clinically and histopathologically confirmed atrophic-erosive OLP or OLL. Participants received 0.5% triamcinolone acetonide mouthrinses following a tapering regimen over 3 months. Basal serum cortisol levels were measured at baseline, after 30 days, and after 90 days of treatment. Clinical and demographic variables and treatment-related adverse effects were analyzed. RESULTS: Mean basal serum cortisol levels decreased from 17.05 ± 4.38 μg/dL at baseline to 8.79 ± 7.34 μg/dL after 1 month of treatment. Following dose tapering, serum cortisol levels (SCL) partially recovered to 11.94 ± 6.44 μg/dL at 3 months. No clinical manifestations of adrenal insufficiency were observed. Baseline SCL were significantly associated with serum cortisol concentrations after 1 month (r = 0.34; p < 0.05). Older patients exhibited smaller hormonal fluctuations during treatment. CONCLUSIONS: Triamcinolone acetonide induced a transient reduction in SCL without clinically relevant adrenal dysfunction, suggesting a limited systemic impact when administered a tapering regimen.
No takes yet. Share an insight, caveat, or question.
Blanco-Aguilera et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: